Canadian Health System Overview
Health System Rankings
Health System Outcomes
Health System Coverage
Costs for Consumers
Health System Expenditures
Canada’s COVID-19 Policy
Expenditure On Retail Pharmaceuticals Per Capita, 2017 (USD$ PPP)
Prescribed Medicines: $681
Over-The-Counter Medicines: $73
Medical Non-Durable: $52
Total: $806
Source: OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/4dd50c09-en.
https://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm
Expenditure On Retail Pharmaceuticals By Type Of Financing, 2017 (%)
Government/Compulsory Plans: 36%
Voluntary Health Insurance Plans: 31%
Out-Of-Pocket: 33%
Other: 0%
Source: OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/4dd50c09-en.
https://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm
“Inpatient drugs are dispensed by hospitals without charge to patients as part of medicare. Outpatient pharmaceuticals, the cost of which may be covered in whole or part through public or private drug plans, are prescribed by physicians and in rare cases by other health providers who have the right to prescribe certain classes of drugs. Individuals obtain their prescription drugs at retail pharmacies. Almost all pharmacies, whether they are independent or part of a chain, sell a host of products beyond prescription and over-the-counter (OTC) drugs. Pharmacies in large chain grocery stores now compete directly with traditional stand-alone pharmacies by selling prescription and OTC drugs. In 2018 there were 10 692 retail pharmacies and drug stores in Canada of which two thirds were commercial chains (IQVIA, 2019).
“Pharmaceutical sales in Canada doubled from 2002 to 2017, with the majority of sales to retail drug stores (88%), and the remainder to hospitals (Canada, 2019d). In 2018 there were 29 802 Canadians employed in pharmaceutical manufacturing, mostly in the three largest cities: Toronto, Montreal and Vancouver. While there is some domestic pharmaceutical production, the majority of the pharmaceuticals in the Canadian market are imported (about 64%), mostly from the USA (38% of all imports) and the European Union (40% of imports) (Canada, 2019d).”
Source: Marchildon G.P., Allin S., Merkur S. Canada: Health system review. Health Systems in Transition, 2020; 22(3): i–194.
https://www.euro.who.int/en/about-us/partners/observatory/publications/health-system-reviews-hits/full-list-of-country-hits/canada-hit-2020
“FPT [Federal, Provincial, and Territorial] governments manage multiple drug plans for their populations; across Canada public drug plans vary in terms of the target populations, formularies and the extent and depth of coverage (CIHI, 2018d; see Chapter 3). There are over 100 public drug plans across the country, since PTs generally administer a catastrophic drug coverage programme for the general population as well as targeted benefits for specific subpopulations such as lower-income people receiving social assistance, older adults aged 65 years and older, and disease specific programmes such as for HIV and cancers. Unlike all other provincial plans, the Quebec drug programme is a mandated insurance plan in which private insurance plays a key role (Pomey et al., 2007). To add further complexity to these PT differences, eligible First Nations and Inuit patients are covered through the federal non-insured health benefits (NIHB) programme administered by Indigenous Services Canada. The one exception to variations in coverage for prescription drugs across jurisdictions is inpatient drug therapy: since prescription drugs provided in hospitals are considered insured health services and part of universal coverage, they are provided by all PT governments to all PT residents, including First Nations and Inuit, free of charge, by PT governments. Geographical variations in drug coverage and costs to individuals reflect this patchwork of programmes in place. For example out-of-pocket (OOP) spending on pharmaceuticals was lowest in Ontario ($ 402 per household, € 272), and highest in Quebec $ 534 per household, € 358); and spending on private drug plan premiums was also lowest in Ontario ($ 153 per household, € 103) and highest in New Brunswick ($ 396 per household, € 265) in 2016 (Morgan, 2018a).”
Source: Marchildon G.P., Allin S., Merkur S. Canada: Health system review. Health Systems in Transition, 2020; 22(3): i–194.
https://www.euro.who.int/en/about-us/partners/observatory/publications/health-system-reviews-hits/full-list-of-country-hits/canada-hit-2020
Health Systems Facts is a project of the Real Reporting Foundation. We provide reliable statistics and other data from authoritative sources regarding health systems in the US and several other nations.
Page last updated Dec. 29, 2020 by Doug McVay, Editor.